NO972707D0 - Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon - Google Patents

Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Info

Publication number
NO972707D0
NO972707D0 NO972707A NO972707A NO972707D0 NO 972707 D0 NO972707 D0 NO 972707D0 NO 972707 A NO972707 A NO 972707A NO 972707 A NO972707 A NO 972707A NO 972707 D0 NO972707 D0 NO 972707D0
Authority
NO
Norway
Prior art keywords
opioid
modulating
receptor function
receptor
function
Prior art date
Application number
NO972707A
Other languages
English (en)
Other versions
NO972707L (no
Inventor
Olivier Civelli
James Richard Martin
Frederick Monsma
Jean-Luc Moreau
Hans-Peter Nothacker
Rainer Reinscheid
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO972707D0 publication Critical patent/NO972707D0/no
Publication of NO972707L publication Critical patent/NO972707L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO972707A 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon NO972707L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96109462 1996-06-13

Publications (2)

Publication Number Publication Date
NO972707D0 true NO972707D0 (no) 1997-06-12
NO972707L NO972707L (no) 1997-12-15

Family

ID=8222893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972707A NO972707L (no) 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Country Status (17)

Country Link
US (2) US6326156B1 (no)
JP (1) JP3212537B2 (no)
KR (1) KR100247670B1 (no)
CN (1) CN1184254A (no)
AR (1) AR007548A1 (no)
AU (1) AU719519B2 (no)
BR (1) BR9703546A (no)
CA (1) CA2206192A1 (no)
CZ (1) CZ179597A3 (no)
HU (1) HUP9701032A3 (no)
IL (1) IL121017A0 (no)
MX (1) MX9704352A (no)
NO (1) NO972707L (no)
NZ (1) NZ328033A (no)
PL (1) PL320527A1 (no)
TR (1) TR199700482A2 (no)
ZA (1) ZA975077B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003279877B2 (en) * 2002-10-07 2010-05-20 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CA2674359A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
AU2010234445A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011097233A1 (en) 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
RU2583435C2 (ru) 2010-07-28 2016-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Ингибиторы faah периферически-ограниченного действия
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP3988540A1 (en) 2014-04-07 2022-04-27 The Regents of the University of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
US6096513A (en) 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
JP4191796B2 (ja) 1995-08-15 2008-12-03 ユーロスクリーン・ソシエテ・アノニム 拮抗剤または作動剤として、ヒトｏｒｌ１受容体に結合できることが知られていない化合物を回収する方法

Also Published As

Publication number Publication date
ZA975077B (en) 1997-12-15
HU9701032D0 (en) 1997-07-28
NZ328033A (en) 1998-11-25
MX9704352A (es) 1997-12-31
US20020082213A1 (en) 2002-06-27
TR199700482A2 (xx) 1998-01-21
AU719519B2 (en) 2000-05-11
PL320527A1 (en) 1997-12-22
CA2206192A1 (en) 1997-12-13
US6326156B1 (en) 2001-12-04
IL121017A0 (en) 1997-11-20
JPH1068724A (ja) 1998-03-10
BR9703546A (pt) 1998-09-29
KR980003586A (ko) 1998-03-30
CZ179597A3 (cs) 1998-03-18
AU2485397A (en) 1997-12-18
NO972707L (no) 1997-12-15
KR100247670B1 (ko) 2000-06-01
CN1184254A (zh) 1998-06-10
AR007548A1 (es) 1999-11-10
HUP9701032A3 (en) 2000-04-28
HUP9701032A2 (hu) 1998-08-28
JP3212537B2 (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
NO986202L (no) FremgangsmÕte for fremstilling av rekombinant adÚnovirus
NO982732D0 (no) Ny fremgangsmÕte
NO972707D0 (no) Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon
NO993068D0 (no) Ny forbindelsesform
NO973245D0 (no) Fremgangsmåte ved komplettering av en underjordisk brönn
FI962932A0 (fi) Ankkuriproteiinifunktion modulaattoreita
NO970362D0 (no) Fremgangsmåte for oppgradering av bensin
NO952072D0 (no) Fremgangsmåte for installering av en eller flere instrumentenheter
NO972022D0 (no) Fremgangsmåte ved fremstilling av papir
DK0810923T3 (da) Fremgangsmåde til trykning
NO971067D0 (no) Fremgangsmåte for oppgradering av bensin
NO952246D0 (no) Fremgangsmåte ved installasjon av strekkstagplattform
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
NO301633B1 (no) Fremgangsmåte ved rakettoverföring
DK0874822T3 (da) Ny fremgangsmåde til fremstilling
ID18300A (id) Metoda penemperan
DE59605202D1 (de) Schnelleinschaltungsverfahren
ID19111A (id) Metoda pembuatan bahan-bahan poliolefin untuk pelapisan
AU4914297A (en) Method of applying dry film photoresist
UA25398A (uk) Спосіб комбіhоваhої холецистолітотомії
UA25653A (uk) Спосіб проведеhhя скальптерапії
UA25135A (uk) Спосіб гастроєюhопластики
UA25353A (uk) Спосіб холецистостомії
NO973547D0 (no) Fremgangsmåte ved fremstilling av papir
GB9619875D0 (en) Method of bridge construction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application